Valeant Pharmaceuticals International Inc. surprised investors Tuesday and maintained its full-year guidance, setting a goal for the second half that will require the drugmaker to substantially raise its sales and profits.
As part of a planned turnaround, Valeant plans to sell assets that the company thinks will be worth about $8 billion, will renegotiate terms with lenders and will reorganize its business into three main segments as it tries to stabilize sales of several important but struggling products.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle20
11:43 For the Record: Thanking SoftBank, annoying Boeing in 140 characters or less6
10:11 The 5 Easiest and 5 Most Difficult Promises for Donald Trump to Keep8
14:14 Lego Group CEO Knudstorp to head new Lego branding division16